Press release from Wave Life Sciences Ltd.
- Business
Announcement Date: September 24, 2024 (U.S. Time)
detail: From Wave Corporation, a key investment of our company, regarding Duchenne muscular dystrophy in boys ( Duchenne muscular dystrophy：DMD ) as an indication for the exon 53 skipping drug WVE-N531 Phase 2a press release has been issued regarding the interim data of the FORWARD-53 clinical trial.For more details Here Read the original press release here.